471 related articles for article (PubMed ID: 27009962)
21. Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice.
Li H; Cao L; Zhang Y; Ren H; Zhao P; Xu W
Arch Virol; 2020 May; 165(5):1057-1067. PubMed ID: 32144542
[TBL] [Abstract][Full Text] [Related]
22. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
Stewart-Jones GBE; Chuang GY; Xu K; Zhou T; Acharya P; Tsybovsky Y; Ou L; Zhang B; Fernandez-Rodriguez B; Gilardi V; Silacci-Fregni C; Beltramello M; Baxa U; Druz A; Kong WP; Thomas PV; Yang Y; Foulds KE; Todd JP; Wei H; Salazar AM; Scorpio DG; Carragher B; Potter CS; Corti D; Mascola JR; Lanzavecchia A; Kwong PD
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12265-12270. PubMed ID: 30420505
[TBL] [Abstract][Full Text] [Related]
24. Clinical Potential of Prefusion RSV F-specific Antibodies.
Rossey I; McLellan JS; Saelens X; Schepens B
Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
26. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
28. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
29. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
30. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
[TBL] [Abstract][Full Text] [Related]
31. Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.
Farrag MA; Amer HM; Öhlschläger P; Hamad ME; Almajhdi FN
Hum Vaccin Immunother; 2017 Jul; 13(7):1586-1597. PubMed ID: 28272978
[TBL] [Abstract][Full Text] [Related]
32. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
34. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
[TBL] [Abstract][Full Text] [Related]
35. HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice.
Li H; Ren H; Zhou Y; Zhang Y; Cao L; Xu W
PLoS One; 2022; 17(1):e0262231. PubMed ID: 35100303
[TBL] [Abstract][Full Text] [Related]
36. Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.
Li H; Ren H; Zhang Y; Cao L; Xu W
Sci Rep; 2021 Sep; 11(1):18641. PubMed ID: 34545126
[TBL] [Abstract][Full Text] [Related]
37. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
38. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
39. Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.
Lee YN; Hwang HS; Kim MC; Lee YT; Kim YJ; Lee FE; Kang SM
Nanomedicine; 2016 Apr; 12(3):759-770. PubMed ID: 26656630
[TBL] [Abstract][Full Text] [Related]
40. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
